Pranamita Sahu

Pranamita Sahu

Auto-generated profile, based on publicly available information

Pranamita Sahu

Medical Research Laboratory, IMS & SUM Hospital, Siksha ‘O’ Anusandhan University Bhubaneswar-751003, Odisha, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in AL-Kindy College Medical Journal
Verified
Journal Article
Open access
PDF file
PSPranamita Sahu
Pranamita Sahu
DDDebasmita Dubey
Debasmita Dubey
SPSoumya Surath Panda
Soumya Surath Panda
STSubrat Kumar Tripathy
Subrat Kumar Tripathy
Obesity is a significant risk factor for colorectal cancer (CRC), influencing its development through multiple biological pathways. Elevated levels of insulin, insulin-like growth factor-1 (IGF-1), leptin, resistin, and inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) contribute to colonic cell proliferation and tumor formation. Additionally, obesity-induced hormonal imbalances, including decreased adiponectin and ghrelin, further increase CRC risk. Changes in gut microbiota due to obesity also play a role in carcinogenesis, highlighting the complex interplay between metabolic, inflammatory, and microbial factors. This review explores the pathophysiological mechanisms linking obesity to CRC, emphasizing its role as a modifiable risk factor. Insulin resistance, chronic inflammation, oxidative stress, and dysregulated adipokine secretion are key contributors to CRC progression in obese individuals. By analyzing molecular and epidemiological evidence, this review underscores the importance of early CRC screening for obese individuals, along with lifestyle modifications such as weight loss, dietary improvements, and increased physical activity. Furthermore, microbiome-targeted interventions, including probiotics and prebiotics, may help counteract obesity-driven dysbiosis and reduce CRC risk. Emerging biomarkers and therapeutic targets offer potential for developing obesity-specific CRC treatments. Given the rising global burden of CRC, integrating preventive healthcare strategies, public health initiatives, and clinical interventions is essential for reducing its incidence and improving patient outcomes. Addressing obesity through targeted preventive measures can significantly lower CRC-related morbidity and mortality, making it a crucial aspect of cancer prevention and management

5 October 2024 in Bangabandhu Sheikh Mujib Medical University Journal
Verified
Journal Article
Open access
PDF file
PSPranamita Sahu
Pranamita Sahu
SMSanghamitra Mihsra
Sanghamitra Mihsra
DDDebasmita Dubey
Debasmita Dubey
There has been a significant increase in antimicrobial resistance, particularly in hospital sectors, after the COVID-19 pandemic. Several factors have led to this situation, and this emergence of antimicrobial resistance, particularly in intensive care units and critical care units, is a severe clinical consternation for the medics. 1 One major factor is the high usage of broad-spectrum antibiotics due to the severity and complexity of intensive care units and critical care unit patients. Secondly, in patients with weakened immune systems in intensive care units, critical care units play a synergistic role in making them susceptible to hospital-acquired infection, warranting the use of a broader spectrum and a combination of antibiotics. 2 Also, invasive devices are frequently used, which increases the risk of infection and leads to empirical therapy with antibiotics, which again drives antibiotic resistance. Further events like cross-transmission between paramedical workers and patients facilitate the spread of resistant bacteria in the hospital and society. Moreover, nosocomial infection is vital in harbouring and transforming antibioticresistant bacteria. Some commonly found antibioticresistant bacteria are methicillin-resistant. 2 This problem is even more severe in lower and middleincome countries, which need more proper medical facilities and well-trained medical personnel.

11 November 2026 in Current Drug Therapy
Verified
Journal Article
Closed access
BDBhabani Shankar Das
Bhabani Shankar Das
RMRajesh Kumar Meher
Rajesh Kumar Meher
PNPradeep Kumar Naik
Pradeep Kumar Naik
SSSmrutipragnya Samal
Smrutipragnya Samal
PSPranamita Sahu
Pranamita Sahu
DDDebasmita Dubey
Debasmita Dubey
Introduction: Ovarian cancer remains a leading cause of cancer-related death in women, necessitating a novel therapeutic strategy with minimal side effects. Lagerstroemia speciosa (L.) Pers., a medicinal plant known for its bioactive phytochemicals, has shown potential to induce apoptosis via the intrinsic mitochondrial pathway. This study evaluated the anticancer activities of L. speciosa leaf methanolic extract (L.sp-Met-Ex) in a preclinical ovarian cancer model and to identify molecular targets through in silico analysis. Methods: Cytotoxicity was assessed via SRB assay on OVCAR-3, SK-OV3, A2780, and HEK-293 cells. Apoptosis, cell cycle arrest, and mitochondrial dysfunction were analyzed using flow cytometry, fluorescent staining, and caspase-9 immunofluorescence. In vivo efficacy was performed in a xenograft model. GC-MS profiling was performed, and in silico prediction was used to explore the Translocator Protein (TSPO) as a potential target. Results: L.sp-Met-Ex exhibited dose-dependent cytotoxicity with IC50 values of 25.4 ± 1.5 μg/ml (OVCAR-3), 49.7 ± 1.7 μg/ml (SK-OV3), and 52.3 ± 1.1 μg/ml (A2780), with minimal toxicity toward HEK-293 cells. Treated cells showed apoptosis marked by nuclear fragmentation, mitochondrial depolarization, elevated ROS, and intracellular calcium levels. The extract significantly suppressed tumor growth in vivo. GC-MS identified key phytocompounds that exhibited stable binding to TSPO in simulations. Discussion: L.sp-Met-Ex demonstrates that it induces mitochondrial-mediated apoptosis via ROS generation, calcium dysregulation, and membrane depolarization. TSPO is implicated as a key molecular target, supporting mitochondrial dysfunction as a therapeutic strategy. Conclusion: L.sp-Met-Ex demonstrates anticancer activity via the intrinsic apoptotic pathway and G2/M phase cell-cycle arrest, highlighting TSPO as a therapeutic potential in ovarian cancer.